Share:
Peer-Reviewed Publication
J Biopharm Stat2026;1-17.May 28, 2026Journal Article

Robust CATE estimation using novel ensemble methods.

Oshri Machluf1, Tzviel Frostig1, Tomer Milo1, Bradley P Carlin1, Elad Berkman1, Raviv Pryluk1
1Research Department, PhaseV Trials, Inc., Cambridge, MA, USA.

Abstract

The estimation of Conditional Average Treatment Effects (CATE) is crucial for understanding the heterogeneity of treatment effects in clinical trials. We evaluate the performance of common methods, including causal forests and various meta-learners, across a diverse set of scenarios, revealing that each of the methods struggles in one or more of the tested scenarios. Given the inherent uncertainty…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.